A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers

Trial Profile

A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Anti-CD3-anti-HER2-activated T-cells (Primary) ; Cyclophosphamide
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 19 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 05 Dec 2016 Planned End Date changed from 1 Aug 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top